How to Buy Agios Pharmaceuticals Stock
Agios Pharmaceuticals Inc
Agios Pharmaceuticals, Inc. , a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology.
Agios Pharmaceuticals stock last closed at $31.49, down 0.57% from the previous day, and has increased 42.49% in one year. It has overperformed other stocks in the Biotechnology industry by 0.65 percentage points. Agios Pharmaceuticals stock is currently +59.08% from its 52-week low of $19.80, and -11.3% from its 52-week high of $35.50.
As of Apr 26, 2024, there are 56.19M shares of AGIO outstanding. The market value of AGIO is $1.77B. In the past 24 hours, 417,224 AGIO shares were traded.
How to Buy Agios Pharmaceuticals Stock
Not sure how to invest in Agios Pharmaceuticals stock? Here's how.
- Figure out where to buy Agios Pharmaceuticals stock: You need to choose a stock brokerage, but don't worry - we've tested dozens of online stock brokerages and apps to help you choose where to buy Agios Pharmaceuticals stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Put funds into your brokerage account: Choose your payment method and add your details.
- Analyze Agios Pharmaceuticals stock: The Agios Pharmaceuticals ticker symbol is AGIO. Is Agios Pharmaceuticals stock a good investment? Should you buy shares of AGIO? How do AGIO's underlying business fundamentals look? Do top analysts think Agios Pharmaceuticals is a good buy? Why has AGIO's stock price moved recently? (Hint: Our stock market analysis tools can help you evaluate if AGIO is a good stock to buy).
- Place your AGIO buy order: Decide if you will purchase AGIO shares at the current market price or use a limit order to buy AGIO stock at a given price.
- Get updates on your AGIO position: Create a watchlist to the latest updates on your new investment in Agios Pharmaceuticals stock.
Step 1: Figure out where to buy Agios Pharmaceuticals stock
You will need an online brokerage account to access the NASDAQ market and buy AGIO stock.
Our favorite brokerage: eToro
Based on our research, eToro is the best online stock brokerage. eToro gives you:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to world markets: From Technology to Utilities, New York to Hong Kong — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro has a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by creating an account with eToro now.
Open eToro AccountStep 2: Create your brokerage account
Now that you've picked your brokerage, you need to fill out some personal information so you are able to buy AGIO today.
How to Start a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal info to create your new brokerage account.
- Submit your information by clicking the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you have created your account on the greatest app to buy stocks, your next step is to transfer the money for your investment:
Check out this video walkthrough for more details transferring funds into your new brokerage account.
Step 4: Analyze Agios Pharmaceuticals stock
After you have chosen the best place to buy Agios Pharmaceuticals stock, it's important to research their stock before you invest, so you truly wrap your head around the risk and upside.
Agios Pharmaceuticals quick stats
Fundamentals of AGIO
WallStreetZen was created to help everyday investors do better fundamental analysis quickly.
You can view all of the due diligence checks on AGIO's stock page.
Is AGIO stock undervalued or overvalued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge AGIO's true value.
Using relative valuations metrics:
- AGIO could be undervalued based on its P/B ratio of 2.18x, relative to Biotechnology industry P/B ratio of 5.85x
You can access additional valuation research on AGIO's stock here.
AGIO Financials at a glance
Signs that AGIO is financially healthy:
- AGIO has a low debt to equity ratio of 0.16.
- AGIO has $776.93M in cash and short term investments. This is sufficient to cover its annual cash burn of $295.74M.
- There are more short-term assets than long-term liabilities on the AGIO balance sheet.
- There are more short-term assets than short-term liabilities on the AGIO balance sheet.
- AGIO has cash burn of 295736000. It has enough cash and short-term investments to cover this for at least one year.
- Total AGIO debt is lower than 5 years ago, relative to shareholder equity.
Signs that AGIO is not financially healthy:
- AGIO profit margin has gone up by 3.15 percentage points in the past year, but the company is still unprofitable.
Is it a good time to buy Agios Pharmaceuticals stock, according to Wall Street analysts?
Out of 3 sell side analysts who give recommendations on AGIO, the consensus analyst rating on Agios Pharmaceuticals is a Hold
Please note that analyst forecasts are not recommendations, nor are they investment advice.
You can dig deeper into what analysts are forecasting on the Agios Pharmaceuticals stock forecast page.
AGIO Trading Indicators
AGIO Revenue
Last year, AGIO revenue was $26.82M. During the last five year, AGIO's revenue has increased by -22.25% per year. This was slower than the Biotechnology industry average of 28.56%.
You can analyze AGIO's earnings and revenue performance here.
Latest Insiders Trades at AGIO
Over the last 12 months, executives and large shareholders at AGIO have sold more shares than they have bought.
Jacqualyn A. Fouse, Director of AGIO, was the latest AGIO insider to sell. They sold $214,642.05 worth of AGIO shares on Apr 10, 2024.
Learn more about who owns AGIO stock here.
Can I rely on AGIO as an income stream?
No, Agios Pharmaceuticals doesn't provide an income stream by paying out dividends.
Get opinions from other traders
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Place your AGIO buy order
There are two main types of orders:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are usually fine. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a particular price, place a limit order.
Hit the Open Trade button and your broker will place the order.
If you need more assistance investing in stocks on eToro, click the helpful video below:
Step 6: Get updates on your AGIO position
Now that you own some shares in AGIO, you'll want to keep up with your new investment.
Make a watchlist to keep tabs on your AGIO stock.
AGIO Feed
How to Buy Stock in Agios Pharmaceuticals
To reiterate, here are the 6 steps to buy stock in Agios Pharmaceuticals:
- Figure out where to buy Agios Pharmaceuticals stock
- Create your brokerage account
- Put funds into your brokerage account
- Analyze Agios Pharmaceuticals stock
- Place your AGIO buy order
- Get updates on your AGIO position
If you are looking for a brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you want to keep track of your investment in Agios Pharmaceuticals, create your watchlist below.
Related "How To" Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.